FDA Approves Lenacapvir: A Breakthrough Twice-Yearly Injection for HIV Prevention
The FDA has approved lenacapvir, the first twice-a-year injection for HIV prevention, showing significant promise in reducing new infections among high-risk populations.
Chicago Sun-TimesTwice-a-year shot to prevent HIV approved by FDA – could stop transmission if people can get it
TIME MagazineFDA Approves a Twice-Yearly Shot to Prevent HIV
NPRHIV prevention drug hailed as a 'breakthrough' gets FDA approval
CBS NewsHIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Overview
The FDA has approved lenacapvir, a twice-yearly injection for HIV prevention, marking a significant advancement in treatment options for high-risk populations.
Clinical trials indicate lenacapvir has nearly eliminated new HIV infections, achieving a 99.9% HIV-negative rate among participants.
Currently, only about 400,000 Americans use PrEP, underscoring the need for improved access and awareness of preventive treatments.
Despite the potential of lenacapvir, over 30,000 new HIV infections occur annually in the U.S., highlighting ongoing challenges in combating the epidemic.
Gilead Sciences plans to produce lenacapvir at no profit for 2 million people in low-income countries until generics are available, aiming to enhance global access.
Analysis
Center-leaning sources frame the FDA's approval of lenacapavir as a significant advancement in HIV prevention, emphasizing its potential to improve adherence and reduce infections. They express cautious optimism, highlighting the need for broader access and the challenges of existing disparities in PrEP usage, reflecting a commitment to public health equity.